References

1. Jaffe ES, Harris NL, Diebold J, et al.: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 111(suppl 1):S8-S12, 1999.

2. Rüdiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 13: 140-149, 2002.

3. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982.

4. Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361-1392, 1994.

5. Jaffe ES, Krenacs L, Raffeld M: Classification of T-cell and NK-cell neoplasms based on the REAL classification. Ann Oncol 8(suppl 2):S17-S24, 1997.

6. Brito-Babapulle V, Pomfret M, Matutes E, et al.: Cytogenetic studies on prolymphocytic leukemia. II: T-cell prolymphocyte leukemia. Blood 70:926-931, 1987.

7. Matutes E, Brito-Babapulle V, Swansbury J, et al.: Clinical and laboratory features of 78 cases of T-pro-lymphocytic leukemia. Blood 78:3269-3274, 1991.

8. Matutes E, Garcia TJ, O'Brien M, et al.: The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 64:111-124, 1986.

9. Hanson CA, Bockenstedt PL, Schnitzer B, et al.: S100-positive, T-cell chronic lymphoproliferative disease: an aggressive disorder of an uncommon T-cell subset. Blood 78:1803-1813, 1991.

survival. Other agents with published activities include the purine analogs and gemcitabine, and these drugs need further study. Recent efforts have focused on the use of targeted therapy, especially the fusion protein denileukin diftitox and the monoclonal Campath-1H/anti-CD52 antibody, which have definite activity in various subsets of T-cell tumors. Other investigational agents including monoclonal antibodies targeting cell surface antigens are under development in various clinical trials at the present time. However, in view of the unsatisfactory outcomes seen in most cases of T-cell lymphoid malignancies, novel therapies should be explored in large, prospective randomized trials involving multiple institutions, and patients with these malignancies should be enrolled on these trials as the first choice of therapy. Potential combinations involving established chemotherapy regimens with emerging targeted therapies that exhibit novel mechanisms of action and nonoverlap-ping toxicities should also be considered for the treatment of T-cell lymphoid malignancies to improve clinical outcomes.

10. Knowles DM: Immunophenotypic and antigen receptor gene rearrangement analysis in T cell neoplasia. Am J Pathol 134:761-785, 1989.

11. McKenna RW, Arthur DC, Gajl-Peczalska KJ, et al.: Granulated T-cell lymphocytosis with neutropenia: malignant or benign chronic lymphoproliferative disorder? Blood 66:259-266, 1985.

12. Loughran TP Jr: Clonal diseases of large granular lymphocytes. Blood 82:1-14, 1993.

13. Pelicci PG, Allavena P, Subar M, et al.: T-cell receptor (alpha, beta, gamma) gene rearrangements and expression in normal and leukemic large granular lymphocytes/natural killer cells. Blood 70:1500-1508, 1987.

14. Sheridan W, Winton EF, Chan WC, et al.: Leukemia of non-T lineage natural killer cells. Blood 72:1701-1707, 1988.

15. Dang NH, Aytac U, Sato K, et al.: T-large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition. Br J Haematol 121:857-865, 2003.

16. Lutzner M, Edelson R, Schein P, et al.: Cutaneous T-cell lymphomas: the Sezary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 83:534-552, 1975.

17. Jones D, Dang NH, Duvic M, et al.: Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 115:885-892, 2001.

18. Haioun C, Gaulard P, Bourquelot P, et al.: Clinical and biological analysis of peripheral T-cell lymphomas: a single institution study. Leuk Lymphoma 7:449-455, 1992.

19. Armitage JO, Vose JM, Linder J, et al.: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma. J Clin Oncol 7:1783-1790, 1989.

20. Cheng AL, Chen YC, Wang CH, et al.: Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparible histological grades—should peripheral T-cell lymphoma be considered separately? J Clin Oncol 7:725-731, 1989.

21. Armitage JO, Greer JP, Levine AM, et al.: Peripheral T-cell lymphoma. Cancer 63:158-163, 1989.

22. Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92:76-82, 1998.

23. Melnyk A, Rodriguez A, Pugh WC, et al.: Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunopheno-type in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 89:4514-4520, 1997.

24. Picker LJ, Weiss LM, Medeiros LJ, et al.: Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma. Am J Pathol 128:181-201, 1987.

25. Suchi T, Lennert K, Tu LY, et al.: Histopathology and immunohistochemistry of peripheral T-cell lymphomas: a proposal for their classification. J Clin Pathol 40:995-1015, 1987.

26. Weiss LM, Crabtree GS, Rouse RV, et al.: Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas. Am J Pathol 118:316-324, 1985.

27. Weiss LM, Trela MJ, Cleary ML et al.: Frequent immuno-globulin and T-cell receptor gene rearrangements in "histiocytic" neoplasms. Am J Pathol 121:369-373, 1985.

28. Frizzera G, Moran EM, Rappaport H: Angio-immunoblastic lymphadenopathy with dyspro-teinaemia. Lancet 1:1070-1073, 1974.

29. Lukes RJ, Tindle BH: Immunoblastic lymphadenopa-thy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med 292:1-8, 1975.

30. Feller AC, Griesser H, Schilling CV, et al.: Clonal gene rearrangement patterns correlate with immunopheno-type and clinical parameters in patients with angioim-munoblastic lymphadenopathy. Am J Pathol 133: 549-556, 1988.

31. Pangalis GA, Moran EM, Nathwani BN, et al.: Angioimmunoblastic lymphadenopathy. Long-term follow-up study. Cancer 52:318-321, 1983.

32. Weiss LM, Strickler JG, Dorfman RF, et al.: Clonal T-cell populations in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Am J Pathol 122:392-397, 1986.

33. Nathwani BN, Rappaport H, Moran EM, et al.: Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer 41:578-606, 1978.

34. Lipford EH, Smith HR, Pittaluga S, et al.: Clonality of angioimmunoblastic lymphadenopathy and implications for its evolution to malignant lymphoma. J Clin Invest 79:637-642, 1987.

35. Godde-Salz E, Feller AC, Lennert K: Chromosomal abnormalities in lymphogranulomatosis X (LgrX)/angioimmunoblastic lyphadenopathy (AILD). Leuk Res 11:181-190, 1987.

36. Anagnostopoulos I, Hummel M, Finn T, et al.: Heterogeneous Epstein-Bar virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 80:1804-1812, 1992.

37. Weiss LM, Jaffe ES, Liu XF, et al.: Detection and localization of Epstein-Barr viral genomes in angioim-

munoblastic lymphadenopathy and angioim-munoblastic lymphadenopathy-like lymphoma. Blood 79:1789-1795, 1992.

38. Abruzzo LV, Schmidt K, Weiss LM, et al.: B-cell lymphoma after angioimmunoblastic lymphadenopathy: a case with oligoclonal gene rearrangements associated with Epstein-Barr virus. Blood 82:241-246, 1993.

39. Shimamoto Y, Suga K, Shibata K, et al.: Clinical importance of extraordinary integration patterns of human T-cell lymphotropic virus type I proviral DNA in adult T-cell leukemia/lymphoma. Blood 84:853-858, 1994.

40. Waldmann TA, White JD, Goldman CK, et al.: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82:1701-1712, 1993.

41. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia- lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-437, 1991.

42. van Krieken JH, Elwood L, Andrade RE et al.: Rearrangement of the T-cell receptor delta chain in T-cell lymphomas with a mature phenotype. Am J Pathol 139:161-168, 1991.

43. Kadin ME, Sako D, Berliner N, et al.: Childhood Ki-1 lymphoma presenting with skin lesions and peripheral lymphadenopathy. Blood 68:1042-1049, 1986.

44. Agnarsson BA, Kadin ME: Ki-1 positive large cell lymphoma. A morphologic and immunologic study of 19 cases. Am J Surg Pathol 12:264-274, 1988.

45. Bitter MA, Franklin WA, Larson RA, et al.: Morphology in K-1 (CD30)—positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2,5)(p23, q35). Am J Surg Pathol 14:305-316, 1990.

46. Greer JP, Kinney MC, Collins RD, et al.: Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma. J Clin Oncol 9:539-547, 1991.

47. Penny RJ, Blaustein JC, Longtine JA, et al.: Ki-1-positive large cell lymphomas, a heterogenous group of neoplasms. Morphologic, immunophenotypic, genotypic, and clinical features of 24 cases. Cancer 68:362-373, 1991.

48. Stein H, Mason DY, Gerdes J, et al.: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66:848-858, 1985.

49. Herbst H, Tippelmann G, Anagnostopoulos I, et al.: Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leuk Res 13:103-116, 1989.

50. Piris M, Brown DC, Gatter KC, et al.: CD30 expression in non-Hodgkin's lymphoma. Histopathology 17: 211-218, 1990.

51. Delsol G, Al Saati T, Gatter KC, et al.: Coexpression of epithelial membrane antigen (EMA), Ki-1, and inter-leukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 130:59-70, 1988.

52. Kaneko Y, Frizzera G, Edamura S, et al.: A novel translocation, t(2;5) (p23;q35), in childhood phagocytic large

T-cell lymphoma mimicking malignant histiocytosis. Blood 73:806-813, 1989.

53. Lopategui JR, Sun LH, Chan JK, et al.: Low frequency association of the t(2;5) (p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study. Am J Pathol 146:323-328, 1995.

54. Mason DY, Bastard C, Rimokh R, et al.: CD30-positive large cell lymphomas ("Ki-1 lymphoma[") are associated with a chromosomal translocation involving 5q35. Br J Haematol 74:161-168, 1990.

55. Falini B, Bigerna B, Fizzotti M, et al.: ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. Am J Pathol 153:875-886, 1998.

56. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al.: ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 91:2076-2084, 1998.

57. Hernandez L, Pinyol M, Hernandez S, et al.: TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood 94(9):3265-3268, 1999.

58. Katzenstein AL, Carrington CB, Liebow AA: Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 43:360-373, 1979.

59. DeRemee RA, Weiland LH, McDonald TJ: Polymorphic reticulosis, lymphomatoid granulomatosis. Two diseases or one? Mayo Clin Proc 53:634-640, 1978.

60. Lipford EH Jr, Margolick JB, Longo DL, et al.: Angiocentric immunoproliferative lesions: a clinico-pathologic spectrum of post-thymic T-cell proliferations. Blood 72:1674-1681, 1988.

61. Simrell CR, Margolick JB, Crabtree GR, et al.: Lymphokine-induced phagocytosis in angiocentric immunoproliferative lesions (AIL) and malignant lymphoma arising in AIL. Blood 65:1469-1676, 1985.

62. Medeiros LJ, Peiper SC, Elwood L, et al.: Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol 22:1150-1157, 1991.

63. Nakamura S, Suchi T, Koshikawa T, et al.: Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 19:284-296, 1995.

64. Chan JK, Ng CS, Lau WH, et al.: Most nasal/nasopha-ryngeal lymphomas are peripheral T-cell neoplasms. Am J Surg Pathol 11:418-429, 1987.

65. Harabuchi Y, Yamanaka N, Kataura A, et al.: Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335:128-130, 1990.

66. Kanavaros P, Lescs MC, Briere J, et al.: Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81:2688-2695, 1993.

67. Chott A, Dragosics B, Radaszkiewicz T: Peripheral T-cell lymphomas of the intestine. Am J Pathol 141: 1361-1371, 1992.

68. Isaacson P, Wright DH: Intestinal lymphoma associated with malabsorption. Lancet 1:67-70, 1978.

69. Murray A, Cuevas EC, Jones DB, et al.: Study of the immunohistochemistry and T-cell clonality of enteropathy-associated T-cell lymphoma. Am J Pathol 146:509-519, 1995.

70. Wright DH, Jones DB, Clark H, et al.: Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes? Lancet 337:1373-1374, 1991.

71. Gonzalez CL, Medeiros LJ, Braziel RM, et al.: T-cell lymphoma involving subcutaneous tissue. A clinicopatho-logic entity commonly associated with hemophago-cytic syndrome. Am J Surg Pathol 15:17-27, 1991.

72. Burg G, Dummer R, Wilhelm M, et al.: A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med 325:1078-1081, 1991.

73. Farcet JP, Gaulard P, Marolleau JP, et al.: Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood 75:2213-2219, 1990.

74. Gaulard P, Bourquelot P, Kanavaros P, et al.: Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of gamma/delta T-cell lymphomas. Am J Pathol 137:617-628, 1990.

75. The Non-Hodgkin's Lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

76. Lopez-Guillermo A, Cid J, Salar A, et al.: Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification. Ann Oncol 9:849-855, 1998.

77. Ansell SM, Habermann TM, Kurtin PJ, et al.: Predictive capacity of the International Prognostic Factor index in patients with peripheral T-cell lymphoma. J Clin Oncol 15:2296-2301, 1997.

78. Reiser M, Josting A, Soltani M, et al.: T-cell Non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 43:805-811, 2002.

79. Armitage JO, Weisenburger DD: New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. J Clin Oncol 16: 2780-2795, 1998.

80. Coiffier B, Brousse N, Peuchmaur M, et al.: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophe-notyped patients treated with the LNH-84 regimen. Ann Oncol 1:45-50, 1990.

81. Weisenburger DD, Anderson JR, Diebold J, et al.: Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. Am J Hematol 67:172-178, 2001.

82. Gascoyne RD, Aoun P, Wu D, et al.: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999.

83. Falini B, Pileri S, Zinzani PL, et al.: ALK+ Lymphoma: clinico-pathological findings and outcome. Blood 93:2697-2706, 1999.

84. Weidmann E: Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 14:991-997, 2000.

85. Matutes E, Taylor GP, Cavenagh J, et al.: Interferon a and zidovudine therapy in adult T-cell leukaemia lymphoma:

response and outcome in 15 patients. Br J Haematol 113: 779-784, 2001.

86. Cheung MMC, Chan JKC, Lau WH, et al.: Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16:70-77, 1998.

87. Kim WS, Song SY, Ahn YC, et al.: CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 12:349-352, 2001.

88. Rodriguez J, Munsell M, Yazji S, et al.: Impact of highdose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 19:3766-3770, 2001.

89. Vose JM, Peterson C, Bierman PJ, et al.: Comparison of high-dose therapy and autologous bone marrow transplantation for T-Cell and B-Cell non-Hodgkin's lymphomas. Blood 76:424-431, 1990.

90. Blystad AK, Enblad G, Kvaloy S, et al.: High-Dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 27:711-716, 2001.

91. Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333: 1540-1545, 1995.

92. Guitart J, Wickless SC, Oyama Yu, et al.: Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138:1359-1365, 2002.

93. Smyth JF, Prentice HG, Proctor S, et al.: Deoxycoformycin in the treatment of leukemias and lymphomas. Ann N Y Acad Sci 451:123-128, 1985.

94. Lofters W, Campbell M, Gibbs WN, et al.: 2'-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 60:2605-2608, 1987.

95. Yamaguchi K, Yul LS, Oda T, et al.: Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult t-cell leukemia. Leuk Res 10: 989-993, 1986.

96. Greiner D, Olsen EA, Petroni G: Pentostatin (2'-deoxy-coformycin) in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 36:950-955, 1997.

97. Monfardini S, Sorio R, Cavalli F, et al.: Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-Cell) and intermediate-and high-grade (T-cell malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group. Oncology 53:163-168, 1996.

98. Mercieca J, Matutes E, Dearden C, et al.: The Role of pentostatin in the treatment of T-Cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12:2588-2593, 1994.

99. Ho AD, Thaler J, Willemze R, et al.: Pentostatin (2'-deoxycoformycin) for the treatment of lymphoid neoplasms. Cancer Treat Rev 17:213-215, 1990.

100. Dearden C, Matutes E, Catovsky D: Deoxycoformycin in the treatment of mature T-cell leukemias. Br J Cancer 64:903-906, 1991.

101. Cummings FJ, Kyungmann K, Neiman RS, et al.: Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J Clin Oncol 9:565-571, 1991.

102. Duggan DB, Anderson JR, Dillman R, et al.: 2'Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: a CALGB phase II study. Med Pediatr Oncol 18:203-206, 1990.

103. Ho AD, Suciu S, Stryckmans P, et al.: Pentostatin in T-cell malignancies, an EORTC phase II trial. Proc Am Soc Clin Oncol 18:13a, 1999.

104. Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17:3117-3121, 1999.

105. Grever MR, Chapman RA, Ratanatharathorn V, et al: An investigation of deoxycoformycin in advanced cutaneous T cell lymphoma (CTCL). Blood 66(suppl 1):215a, 1986.

106. Verstovek S, Cabanillas F, Dang NH: CD26 in T-cell lymphomas: a potential clinical role? Oncology 14(suppl 2):17-23, 2000.

107. Dang NH, Hagemeister FB, Duvic M, et al.: Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes. Oncol Rep 10:1513-1518, 2003.

108. Kong LR, Samuelson E, Rosen ST, et al.: 2-Chlorodeoxyadenosine in cutaneous T-cell lympho-proliferative disorders. Leuk Lymphoma 26:89-97, 1997.

109. Kuzel TM, Hurria A, Samuelson E, et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 87:906-911, 1996.

110. O'Brien S, Kurzrock R, Duvic M, et al.: 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 84:733-738, 1994.

111. Von Hoff DD, Dahlberg S, Hartstock RJ, et al.: Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst 82: 1353-1355, 1990.

112. Redman JR, Cabanillas F, Velasquez WS, et al.: Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol 10:790-794, 1992.

113. Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/sézary syndrome. J Clin Oncol 10: 1907-1913, 1992.

114. Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/sezary syndrome. J Clin Oncol 12:2051-2059, 1994.

115. Scarisbrick JJ, Child JF, Clift A, et al.: A trial of fludara-bine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. Br J Dermatol 144: 1010-1015, 2001.

116. Au WY, Ng WM, Choy C, et al.: Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexam-ethasone. Br J Dermatol 143:408-410, 2000.

117. Zinzani PL, Baliva G, Magagnoli M, et al.: Gemcitabine treatment in pretreated cutaneous t-cell lymphoma: experience in 44 Patients. J Clin Oncol 18:2603-2606, 2000.

118. Sallah S, Wan JY, Nguyen NP: Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 113:185-187, 2001.

119. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19:376-388, 2001.

120. Foss FM: DAB389IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 1:110-116, 2000.

121. Foss FM, Bacha P, Osann KE, et al.: Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 1:298-302, 2001.

122. Talpur R, Apisarnthanarax N, Ward S, et al.: Treatment of refractory peripheral t-cell lymphoma with denileukin diftitox (ONTAK®). Leuk Lymphoma 43:121-126, 2002.

123. McGinnis KS, Shapiro M, Junkins-Hopkins JM, et al.: Denileukin diftitox for the treatment of panniculitic lymphoma. Arch Dermatol 138:740-742, 2002.

124. Gilleece MH, Dexter TM: Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807-812, 1993.

125. Treumann A, Lifely MR, Schneider P, et al.: Primary structure of CD52*. J Biol Chem 270:6088-6099, 1995.

126. Ginaldi L, De Martinis M, Matutes E, et al.: Levels of expression of CD52 in normal and leukemic b and t Cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 22:185-191, 1998.

127. Dyer MJS, Hale G, Hayhoe FGJ, et al.: Effects of CAM-PATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73:1431-1439, 1989.

128. Dearden CE, Matutes E, Cazin B, et al.: High remission rate in T-cell prolymphocytic leukemia with CAM-PATH-1H. Blood 98:1721-1726, 2001.

129. Keating MJ, Cazin B, Coutre S, et al.: Campath-1H treatment of T-Cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20:205-213, 2002.

130. Lundin J, Österborg A, Brittinger G, et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. J Clin Oncol 6:3257-3263, 1998.

This page intentionally left blank

0 0

Post a comment